Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and

Here is how Acadia Pharmaceuticals (ACAD) and Amneal Pharmaceuticals (AMRX) have performed compared

Acadia Pharmaceuticals (ACAD) shares have started gaining and might continue moving higher in the ne

As investors look to balance growth opportunities with defensive positioning, Acadia Pharmaceuticals

Oppenheimer analyst Matthew Hershenhorn maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Per

Acadia beats Q2 earnings and revenue estimates as strong Daybue and Nuplazid sales lift results and

RBC Capital analyst Brian Abrahams maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperfo

Citizens analyst Jason N. Butler maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Market Out

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2026 Earnings Call Transcript

Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.18 per share, beating the Zacks

ACADIA Pharmaceuticals NASDAQ: ACAD reported second-quarter 2026 revenue of $308 million, representi

ACADIA Pharmaceuticals (NASDAQ:ACAD) raises FY2026 sales outlook from $1.220 billion-$1.280 billion

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported quarterly earnings of $0.18 per share which beat the a

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financia

Avidity Partners Management LP cut its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ: AC

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat

Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 result

Acadia Pharmaceuticals Inc. ended July on a high note. The top line results from the Phase 2 RADIANT

The mean of analysts' price targets for Acadia (ACAD) points to a 30.9% upside in the stock. While t

Bessemer Group Inc. lifted its stake in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) by 21,126.8% duri

ACAD wins FDA's Fast Track status for remlifanserin in Alzheimer's disease psychosis as its phase II

BMO Capital analyst Evan David Seigerman maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Ou

Wall Street analysts change outlook on top names. See all rating changes, including upgrades and dow

Stifel analyst Paul Matteis maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Hold and raises

Allspring Global Investments Holdings LLC lifted its stake in ACADIA Pharmaceuticals Inc. (NASDAQ: A

-- Designation underscores the significant unmet need for new treatment options for Alzheimer’s dise

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S.

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will

RBC Capital analyst Brian Abrahams maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperfo

B of A Securities analyst Tazeen Ahmad maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy

Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and

Canaccord Genuity analyst Sumant Kulkarni maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a B

Acadia shares rise after CHMP recommends DAYBU for Rett syndrome in the European Union, reversing an

U.S. stocks slightly up, Dow Jones gains 0.1%. Health care shares jump 2.8%, ON Semiconductor down 2

Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected f

Gainers Quantum Cyber (NASDAQ:QUCY) stock moved upwards by 63.4% to $2.37 during Friday's pre-m

-- European Commission decision expected in the coming months-- If approved, DAYBU® would become the

Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and

ACADIA Pharmaceuticals (NASDAQ:ACAD) affirms FY2026 sales outlook from $1.220 billion-$1.280 billion

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported quarterly earnings of $0.02 per share which missed the

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will present multiple original dat

-- DAYBUE STIX is a new powder formulation of trofinetide-- Recently published expert consensus reco

Top Wall Street analysts changed outlook on top names. See all rating changes, including upgrades, d

B of A Securities analyst Tazeen Ahmad upgrades ACADIA Pharmaceuticals (NASDAQ:ACAD) from Neutral

JP Morgan analyst Tessa Romero maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight a

TD Cowen analyst Ritu Baral maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises

RBC Capital analyst Brian Abrahams maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperfo